Lantheus Holdings, Inc. (LNTH) Stock

Lantheus Holdings, Inc. specializes in the development, manufacturing, and global commercialization of diagnostic and therapeutic products designed to aid clinicians in diagnosing and treating a wide range of diseases, with a focus on heart conditions, cancer, and other critical illnesses. The company offers a diverse portfolio of essential medical solutions including DEFINITY, a microbubble ultrasound enhancing agent used for heart ultrasound exams, and TechneLite, a technetium generator essential for nuclear medicine procedures.

Among its diagnostic products, Lantheus provides Xenon-133 for assessing pulmonary function, Neurolite for identifying brain areas affected by stroke-related blood flow reductions, and Cardiolite, an injectable imaging agent crucial for myocardial perfusion studies. The company also supplies therapeutic products such as AZEDRA, a radiotherapeutic treatment for adult and pediatric patients, and the Automated Bone Scan Index, which quantifies prostate cancer's disease burden through bone scan analysis.

Lantheus Holdings further supports medical professionals with essential products like RELISTOR for opioid-induced constipation, PYLARIFY for detecting recurrent prostate cancer in lymph nodes, bone, and soft tissues, and Flurpiridaz F 18 for assessing cardiac blood flow. The company's robust pipeline includes LMI 1195 for neuroblastoma tumors and innovative technologies like PYLARIFY AI, an AI-based software for standardized quantitative assessment of PSMA PET/CT images in prostate cancer diagnosis.

With a customer base spanning radio pharmacies, distributors, hospitals, clinics, and group practices worldwide, Lantheus Holdings has established strategic partnerships with leading entities such as NanoMab Technology Limited, Bausch Health Companies, GE Healthcare, and Regeneron Pharmaceuticals. Founded in 1956 and headquartered in North Billerica, Massachusetts, Lantheus continues to innovate in medical imaging and therapeutic solutions, advancing healthcare outcomes globally.